Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?

by Zacks Equity Research

Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.

    Zacks Equity Research

    Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

    by Zacks Equity Research

    Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

      Sweta Killa headshot

      Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)?

      by Sweta Killa

      Sector ETF report for PBE

        Zacks Equity Research

        QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff

        by Zacks Equity Research

        QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.

          Zacks Equity Research

          Medtronic Initiates Study on DES for Expanded Use in the US

          by Zacks Equity Research

          Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.

            Zacks Equity Research

            Illumina Takes Over Edico Genome, Fortifies NGS Platform

            by Zacks Equity Research

            Illumina (ILMN) proceeds with deals to boost NGS platform.

              Zacks Equity Research

              Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

              by Zacks Equity Research

              FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

                Zacks Equity Research

                Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

                by Zacks Equity Research

                Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

                  Tirthankar Chakraborty headshot

                  5 Winning Stocks With Superb Efficiency Level

                  by Tirthankar Chakraborty

                  A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                    Zacks Equity Research

                    Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina

                    by Zacks Equity Research

                    Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina